The DEA is requiring eight hours of training on treating and managing patients with opioid and other substance abuse disorders to meet new MATE compliance.
By David Palmer, Esq.
The Drug Enforcement Administration (DEA) has announced a new requirement for all practitioners seeking an initial or renewal DEA registration to dispense controlled substances in schedules II, III, IV, or V.
In addition, the Medication Access and Training Expansion (MATE) Act was passed as part of the Consolidated Appropriations Act of 2023 and requires a one-time, eight-hour training on treating and managing patients with opioid and other substance use disorders.
Beginning for all initial and renewal registrations on or after June 27, 2023, prescribers will be required to check a box on their DEA registration form affirming that they have completed the eight hours of one-time training on safe controlled substance prescribing.
This training does not have to occur in one session. The training can be cumulative across multiple sessions that equal eight hours of training and can happen in various formats, including classroom settings, seminars, or electronically. The DEA has stated that this training is a one-time requirement, and registrants will not be required to complete it again in subsequent years.
While the DEA has not released a plan to audit compliance with this training, registrants should maintain all certificates of completion to be readily available upon request from the DEA.
Take the Course Live or at Your Convenience
DEA MATE COMPLIANCE Treatment and Management of Patients with Opioid or Other Substance Abuse Disorders is an eight-hour course being offered to satisfy this requirement and will cover various topics related to opioid prescribing and pain management, such as:
- The risks and benefits of opioids.
- Safe pharmacological management of dental pain and screening.
- Treatment and management of patients with substance abuse disorders.
- Patient counseling and education.
- The appropriate clinical use of all drugs approved by the Food and Drug Administration for treating a substance use disorder.
This course will be presented live on April 29, 2023, and taught by world-renowned faculty members Steve Yun, MD, Leslie Fang, MD, Ph.D., John Hexem, MD, and Carol Wilson, DMD
For those who cannot attend the live-stream course on April 29 or miss any portion of the live course, you will have access to the presentation recording to view at your convenience.
Registration qualifies you to access the complete recording of this course for one (1) year from the date you registered. You must take (and pass) a quiz for online content to qualify for the entire eight hours of CE.
The Drug Enforcement Administration does not approve specific courses, only specific educational providers. Meharry Medical College, a DEA-approved CERP provider, will issue the certificate upon completing this course.
Should you have any questions about these new requirements, please get in touch with DOCS regulatory counsel David Palmer, Esq. at [email protected].
If you're not yet subscribed to receive the Incisor newsletter, filled with cutting-edge dental news sent directly to your inbox twice a month, you can do so here.
Author: David Palmer, Esq. is an attorney licensed in the Commonwealth of Pennsylvania. Having spent time in both private and corporate practice, he specializes in compliance, contract negotiation, insurance regulations, and healthcare. Outside of the office, David enjoys traveling and the outdoors.
